Spyre Therapeutics, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Spyre announced positive topline induction data for SPY001 and SPY002 in the Phase 2 SKYLINE trial for ulcerative colitis, with SPY001 achieving a 9.2-point reduction in Robart's Histopathology Index and 40% clinical remission rate; SPY002 achieved 10.7-point reduction and 33% remission. The company completed enrollment in the Phase 2 SKYWAY basket trial across three rheumatic disease sub-studies (RA, PsA, axSpA) and maintains $1,145.3 million in cash as of June 30, 2026, providing runway into H2 2029. Six Phase 2 proof-of-concept readouts are expected in 2026–2027.
Why this rating
Positive clinical efficacy data in lead program materially de-risks pipeline; $435M raised in April 2026 extends runway significantly. For a $1.1B-market-cap clinical-stage biotech, Phase 2 proof-of-concept hits in key indications and strong cash position represent meaningful progress, though regulatory approval remains years away.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.